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Inflammatory diseases of the gastrointestinal tract are emerging as a global problem with
increased evidence and prevalence in numerous countries. A dysregulated sphingolipid
metabolism occurs in patients with ulcerative colitis and is discussed to contribute to its
pathogenesis. In the present study, we determined the impact of acid sphingomyelinase
(Asm), which catalyzes the hydrolysis of sphingomyelin to ceramide, on the course of
Citrobacter (C.) rodentium-driven colitis.C. rodentium is an enteric pathogen and induces
colonic inflammation very similar to the pathology in patients with ulcerative colitis. We
found that mice with Asm deficiency or Asm inhibition were strongly susceptible to C.
rodentium infection. These mice showed increased levels of C. rodentium in the feces
and were prone to bacterial spreading to the systemic organs. In addition, mice lacking
Asm activity showed an uncontrolled inflammatory Th1 and Th17 response, which was
accompanied by a stronger colonic pathology compared to infected wild type mice.
These findings identified Asm as an essential regulator of mucosal immunity to the
enteric pathogen C. rodentium.
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INTRODUCTION
Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease, are characterized
by chronic, relapsing inflammatory conditions, resulting from a dysregulation of the mucosal
immune system in the gastrointestinal tract (1). The exact mechanism underlying the pathogenesis
of IBD is unknown; however, it is widely accepted that immunological abnormalities, genetic and
environmental factors, as well as infections are important determinants of IBD (2).
Sphingolipids are a family of metabolic lipids that are ubiquitous in cellular membranes and
include a bioactive subset that regulates various cellular mechanisms and biologic processes such
as cell survival, growth, differentiation, and apoptosis (3). Interestingly, sphingolipids are also
essential structural components of intestinal membranes, providing protection and integrity to the
intestinal mucosa and regulating intestinal absorption processes (4, 5). Studies using common acute
and chronic epithelial injury colitis models have shown that bioactive sphingolipids, particularly
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ceramide and sphingosine-1-phosphate, are important regulators
of inflammation in IBD (6–8). The acid sphingomyelinase (Asm)
is a relevant enzyme in this context, as it catalyzes the hydrolysis
of sphingomyelin to ceramide. Asm is ubiquitously expressed and
activated by a range of cellular stresses, including inflammatory
cytokines and pathogens (9). The importance of Asm for cell
functions was first recognized in Niemann-Pick disease type
A and B, a genetic disorder with a severe accumulation of
sphingomyelin in many organs (10). Recent studies implicated
that Asm activity is also strongly involved in inflammatory
processes (11). For example, Asm inhibition was shown to
suppress the lipopolysaccharide (LPS) mediated release of
inflammatory cytokines and to protect against disease pathology
in chemical induced colitis in mice (12, 13). Furthermore,
blockade of Asm bioactivity limited the in vitro differentiation
of T helper cells derived from healthy volunteers and patients
with Crohn’s disease (14). These results implicate Asm inhibition
as an innovative and effective immunoregulatory strategy for the
treatment of IBD (12, 13, 15).
Nevertheless, the etiology of IBD is diverse and influenced by
numerous factors (2). In this context, several enteropathogens
have been implicated in the development of IBD (16), although
to date, a causative bacterial agent for IBD has not been
identified. Thus, further studies are needed to clarify the function
of Asm under infectious and non-infectious conditions, as
broad immunosuppression can increase the risk of infectious
complications (17).
In the present study, we determined the impact of Asm activity
on the course of Citrobacter (C.) rodentium induced colitis. In
contrast to the protective effect of Asm inhibition in common
acute and chronic epithelial injury colitis models, Asm inhibition
or Asm deficiency strongly enhanced the susceptibility to enteric
C. rodentium infection. Mice lacking Asm activity showed higher
colon pathology, were prone to bacterial dissemination to the
systemic organs, and showed an uncontrolled inflammatory
Th1 and Th17 response compared to infected wild type mice.
These findings identified Asm as a critical regulator of mucosal
immunity to the enteric pathogen C. rodentium.
MATERIALS AND METHODS
Mice
C57BL/6 mice were purchased from ENVIGO, Netherlands.
To inhibit acid sphingomyelinase activity, amitriptyline or
imipramine was administered to C57BL/6 mice at 180 mg/l via
drinking water for 14 days prior to bacterial challenge, and for
further 10 days of infection. Acid sphingomyelinase-deficient
(Smpd1−/−) mice (18) were bred at the animal facility of the
University Hospital Essen. All animals used in this study were 8–
12 week old male or female mice kept in the animal experimental
unit of the University Hospital Essen in individually ventilated
cages and pathogen free conditions.
Asm Activity
The activity of Asm in colonic tissue was quantified using
BODIPY-labeled sphingomyelin as a substrate. After
colonic tissue was pulverized and lysed in 250mM sodium
acetate (pH 5) and 1% NP-40, 2 µg protein was incubated
with 100 pmol BODIPY-labeled sphingomyelin (Thermo
Fisher Scientific, Germany) for 1 h at 37◦C in 250mM
sodium actetate (pH 5) and 0.1% NP-40. The reaction was
terminated by the addition of chloroform:methanol (2:1,
v:v) to extract the lipids. Subsequently, the lower phase
containing lipids was collected, dried in a SpeedVac at
37◦C, dissolved in 20 µl chloroform:methanol (2:1, v:v)
and transferred onto a thin layer chromatography (TLC)
plate. Product and uncleaved substrate were separated using
chloroform:methanol (80:20, v/v). After separation, spots




Ceramide and sphingomyelin concentrations were quantified
by rapid resolution liquid chromatography/mass spectrometry.
Short lipids were extracted from colon biopsies with C17-
ceramide and C16-d31sphingomyelin as internal standards,
after homogenization of colonic tissue. Subsequently, samples
were analyzed by rapid-resolution liquid chromatography-
MS/MS using a Q-TOF 6530 mass spectrometer (Agilent
Technologies, Waldbronn, Germany) operating in the positive
ESI mode. The subsequent quantification was performed
using Mass Hunter Software, and the resulting sphingolipid
quantities were normalized to the actual protein content of
the homogenate.
C. rodentium Infection Model
C. rodentium ICC169 strain was cultured overnight in Luria-
Bertani (LB) medium at 37◦C, centrifuged and washed with
PBS. Mice were infected by oral gavage with ∼2 × 109 colony
forming units (CFUs) of C. rodentium. After gavage, an aliquot
of the bacteria was plated in serial dilutions on MacConkey agar.
Bacterial numbers in the feces were determined at indicated time
points after infection. Mice were analyzed at various time points
after infection (d.p. infection).
Intestinal Permeability-Assay
For in vivo analysis of the intestinal permeability fluorescein
isothiocyanate-conjugated (FITC)-dextran beads have been used.
Briefly, food and water were withdrawn for 2 h and mice were
orally administrated with permeability tracer (60 mg/100 g body
weight of FITC-labeled dextran, MW 4000; FD4, Sigma-Aldrich,
St. Louis, USA). Serum was collected 4 h later and fluorescence
intensity was determined (excitation, 492 nm; emission, 525 nm;
BioTek). FITC-dextran concentrations were determined using a
standard curve generated by serial dilution of FITC-dextran.
Isolation of Splenocytes and Mesenteric
Lymph Node Cells
Spleens were rinsed with an erythrocyte lysis buffer
[containing 0.15M NH4Cl, 10mM KHCO3, and 0.5M
ethylenediaminetetraacetic acid (EDTA)], meshed through
a 100-µm cell strainer, and washed with PBS containing 2mM
EDTA and 2% fetal calf serum (FCS). Mesenteric lymph nodes
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(mLN) were meshed through a 100-µm cell strainer and washed
with PBS containing 2mM EDTA and 2% FCS.
Isolation of Lamina Propria Lymphocytes
From the Colon
Lamina propria (LP) lymphocytes were isolated as described
previously (19). In brief, colons were flushed with PBS, opened
longitudinally, and cut into 1-cm pieces. Tissue pieces were
washed twice in PBS containing 3mM EDTA for 10min at 37◦C
and twice in Roswell Park Memorial Institute (RPMI) medium
containing 1% FCS, 1mM EGTA, and 1.5mM MgCl2 for
15min at 37◦C. Colon pieces were intensively vortexed, washed
with phosphate-buffered saline (PBS), and digested in RPMI
containing 20% FCS and 100 U/mL collagenase (Clostridium
histolyticum; Sigma-Aldrich, St. Louis, MO) for 60min at 37◦C.
Cell suspension was passed through a 40-µm cell strainer and
washed with culture medium.
Macroscopic and Histopathologic
Assessment of Colitis
Colonic damage was assessed based on two main characteristics:
colon length and colon weight. Colons were embedded in
paraffin, and tissue sections (4µm)were prepared for histological
scoring in a blinded manner. The colon was divided into
three equal portions (oral, middle, and rectal) and assessed
for inflammatory cell infiltrates, epithelial damage, neutrophil
infiltration, crypt abscesses, and crypt hyperplasia as describe
before (20). Crypt heights were measured by micrometry; 30
measurements were taken in the distal colon for each mouse.
Cytokine Detection
Cytokines in serum samples were quantified using a Procarta
Cytokine assay kit, according to the manufacturer’s guidelines.
The assay was run on a Luminex 200 system and cytokine
levels were quantified using the Luminex IS software (Luminex
Corporation, Austin, TX).
Antibodies and Flow Cytometry
Cells were stained with fluorochrome-labeled anti-mouse CD4
(RM4-5), CD11b (M1/70), F4/80 (BM8), FoxP3 (FJK-16s), IFNγ
(XMG1.2), IL-17 (TC11-18H10.1), and I-A/I-E (M5/114.15.2)
antibodies and analyzed by flow cytometry on an LSR II
instrument using DIVA software (BD Biosciences).
Statistical Analysis
Normality of data was tested using D’Agostino & Pearson
normality test and Shapiro–Wilk normality test. Statistical
analysis was performed using Student’s t-test, one-way ANOVA
or two-way ANOVA followed by Tukey’s multiple comparisons
test, Dunn’s multiple comparisons test or Bonferroni’s multiple
comparisons test. P-values were set at a level of p < 0.05.
Statistical analyzes were performed using GraphPad Prism
software version 7.
Ethics Statement
This study was carried out in accordance with the
recommendations of the Society for Laboratory Animal Science
(GV-SOLAS) and the European Health Law of the Federation
of Laboratory Animal Science Associations (FELASA). The
protocol was approved by the North Rhine-Westphalia State
Agency for Nature, Environment and Consumer Protection
(LANUF), Germany.
RESULTS
Alterations of the Sphingolipid Profile
During C. rodentium Infection
Sphingolipids have been identified as important players to
control intestinal inflammation. There is increasing evidence
that a dyregulaton of several sphingolipid molecules occurs
along with IBD and contributes to the pathogenesis and
maintenance of the disease (21). To analyze the impact of
the sphingolipid metabolism on pathogen-driven intestinal
inflammation, C57BL/6 wild type (WT) mice were infected
via oral gavage with ∼2 × 109 CFUs C. rodentium, and the
sphingomyelin and ceramide concentrations were determined
in the colon at indicated time points post infection by
mass spectrometry. Interestingly, sphingomyelin as well as
ceramide concentrations in the colon decreased during the
course of infection in comparison to non-infected WT mice
(Figures 1A,B), suggesting an involvement of the sphingolipid
metabolism in intestinal inflammation.
Oral Amitriptyline Pre-treatment Inhibits
the Colonic Asm Activity During
C. rodentium Infection
Acid sphingomyelinase (Asm) metabolizes sphingomyelin into
ceramide, and this enzyme can be pharmacologically inhibited
by amitriptyline (Ami) (22, 23). Amitriptyline accumulates in
the acid compartments of the lysosomes, interferes with the
translocation of Asm to the outer leaflet of the membrane
and inhibits the activation of Asm (9). As sphingomyelin and
ceramide were downregulated during the course of C. rodentium
infection, we tested if the inhibition of Asm protects from
pathogen-driven intestinal inflammation. For the specific in vivo
inhibition of Asm in the gastrointestinal tract, WT mice were
provided with amitriptyline in the drinking water for 14 days
before and during a 10 day course of infection (WT/Ami). To
check for the inhibition of the Asm activity, colonic tissues of
WT/Amimice, infected and non-infected, were analyzed for their
sphingolipid profile by mass spectroscopy during the course of
infection. Although no differences in the sphingomyelin and
ceramide concentration were discovered under homeostasis, we
detected an accumulation of sphingomyelin and ceramide in
the colon of infected WT/Ami mice with constant increase
during the course of infection (Figures 1C,D). This data clearly
demonstrated a modulation of the sphingolipid pathway in the
colonic tissue by amitriptyline treatment via the drinking water.
Asm Inhibition Increases the Susceptibility
to C. rodentium Infection
To further elucidate the physiological effect of Asm inhibition
on the course of infection, we characterized the C. rodentium
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FIGURE 1 | Alterations of sphingolipid concentrations during C. rodentium infection. C57BL/6 mice were either left untreated (WT) or pre-treated with 180 mg/l
amitriptyline in drinking water 2 weeks prior to infection (WT/Ami) and during the course of infection. Mice were orally gavaged with PBS or with ∼2 × 109 colony
forming units (CFUs) of C. rodentium. At indicated days post (dp) infection colons were excised. In rectal colonic tissue, the (A,C) sphingomyelin and (B,D) ceramide
contents were analyzed using rapid resolution liquid chromatography/mass spectrometry. Data are presented as the concentration of ceramide and sphingomyelin in
pmol/mg protein. All data are presented as mean ± SEM. Statistics were performed using the parametric one-way ANOVA test with Tukey’s multiple comparison test
(*p < 0.05; **p < 0.01).
induced inflammatory response in WT and WT/Ami mice in
detail. First, we determined the body weight loss of the mice
as indicator for diarrhea. Surprisingly, C. rodentium infected
WT/Ami mice lost significantly more body weight within 5 and
10 days post infection compared to infected wild type mice
(Figure 2A). Determination of the bacterial burden in the feces
showed that bacterial loads were similar in WT and WT/Ami
infected mice on day 3 post infection with 107 CFUs/g of
feces. However, C. rodentium infected WT/Ami mice exhibited
significantly higher bacterial numbers at day 5 and 7 post
infection than did infected WT mice (Figure 2B), suggesting
an impairment in the clearance of the pathogen. Interestingly,
reduced bacterial eradication in WT/Ami mice was associated
with exaggerated inflammation, characterized phenotypically by
higher spleen weights (Figure 2C) and significantly higher colon
weight-to-length ratios (Figure 2D) than in infected WT mice
10 days post infection. Well in line, histological analysis of
the colon showed that C. rodentium-infected WT/Ami mice
exhibited more severe crypt elongation and crypt hyperplasia
(Figures 2E,F) and a higher inflammatory score compared to
infected WT mice (Figure 2G). Of note, the same phenotype
was obtained when infected mice were treated daily with
amitriptyline via intraperitoneal injection (data not shown).
These findings indicate that Asm activity is not only important
for the eradication of C. rodentium but also for the control of
infection-associated inflammation. Therefore, inhibition of Asm
is not protective in pathogen-driven intestinal inflammation.
Asm Provides Host Resistance to
Bacterial Dissemination
A consequence of certain enteric bacterial infections is a
breakdown of the intestinal barrier, allowing pathogen spreading
from the intestine to the systemic organs of a host. Therefore, we
tested whether Asm inhibition affects the intestinal permeability
in vivo. Non-infected and infected WT and WT/Ami mice were
orally gavaged with FITC-labeled dextran beads and 4 h later the
intestinal permeability was assessed as relative concentration of
serum FITC-dextran. Interestingly, the FITC concentrations in
the serum of WT/Ami mice were significantly increased when
compared to non-infected WT/Ami controls (Figure 3B). In
contrast, only a slight but not significant increase in serum
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FIGURE 2 | Amitriptyline pre-treatment increases the susceptibility to C. rodentium challenge. C57BL/6 mice were treated as described in Figure 1. (A,B) At
indicated time points body weight and CFUs in feces in WT mice (white squares; n = 32–33) and WT/Ami mice (black squares; n = 32–35) were assessed. Statistics
were performed using the Mann–Whitney test. (C) Spleen weight (n = 9–32) and (D) colon weight-to-length ratio were determined in uninfected, untreated and
uninfected amitriptyline treated mice 5 and 10 dp C. rodentium infection (n = 9–32). (E) Representative H&E staining of colon sections from PBS or C. rodentium
infected WT or WT/Ami mice 10 dp challenge. [Red lines indicate the crypt length. (L) lumen, (C) crypt. Length of scale bar is 50µm]. (F) Measured crypt length in
(Continued)
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FIGURE 2 | colons of uninfected WT or WT/Ami mice, and infected WT and WT/Ami 10 dp C. rodentium infection (n = 4–18). (G) Histopathology score of uninfected
WT and WT/Ami mice, and WT and WT/Ami mice 10 dp C. rodentium infection (n = 4–18). All data are presented as mean ± SEM. Statistics were performed using
the two-way ANOVA test followed by Tukey’s multiple comparison test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
FIGURE 3 | Enhanced systemic distribution of C. rodentium in mice pre-treated with amitriptyline. C57BL/6 mice were treated and infected as described in Figure 1.
(A,B) Mice were orally administrated with FITC-labeled dextran beads. Serum was collected 4 h later, and fluorescence intensity was determined (n = 5). Serum FITC
concentration in infected mice was normalized to serum FITC concentration of the respective control. (C,D) 5 and 10 dp C. rodentium infection spleen and liver were
isolated and CFUs of C. rodentium were assessed (n = 13–27). (E–G) Concentration of the cytokines IL12p70, IFNγ, and TNFα in serum of WT and WT/Ami mice 10
dp C. rodentium infection were measured using Luminex technologies (n = 18–37). All data are presented as mean ± SEM. Statistics were performed using the
Mann–Whitney test or Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
FITC levels was detected in infected WT mice compared to
non-infected WT mice (Figure 3A).
These results led us to hypothesize that bacteria, once invaded
into the gastrointestinal tract, are spread to the systemic organs
of infected WT/Ami mice. Thus, we infected WT and WT/Ami
mice via oral gavage with ∼2 × 109 CFUs C. rodentium
per mouse, harvested the spleen and liver 5 and 10 days
post-infection and analyzed the presence of viable bacteria. Well
in line with the permeability assay, a higher bacterial burden
was observed in the livers and spleens of infected WT/Ami mice
compared to infected WT mice (Figures 3C,D).
The production of protective cytokines is a hallmark of
immune responses being mounted toward the infection. To
assess if the systemic distribution of C. rodentium in WT/Ami
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FIGURE 4 | Infiltration of macrophages into colonic tissue is not altered in amitriptyline pre-treated mice after C. rodentium challenge. C57BL/6 mice were treated as
described in Figure 2. Cells from the spleen, mesenteric lymph nodes (mLNs), and the lamina propria (LP) were isolated from uninfected WT and WT/Ami mice, 5 and
10 days post C. rodentium infection and analyzed for the frequency for macrophages by flow cytometry. (A) Percentages of macrophages from living cells are
displayed (n = 7–25). (B) MFI of MHCII from macrophages is displayed (n = 7–25). All data are presented as mean ± SEM. Statistics were performed using the
two-way ANOVA test with Tukey’s multiple comparison test (*p < 0.05; **p < 0.01; ****p < 0.0001).
mice altered the level of cytokines that have been shown to
orchestrate the immune response against C. rodentium infection
(24), we infected WT and WT/Ami mice and measured the
cytokine levels of IL-12p70, IFNγ, and TNFα in the sera. Of
note, we found significantly elevated levels of IL12p70, INFγ,
and TNFα in the sera of infected WT/Ami mice on day 10 post
infection compared to infectedWTmice (Figures 3E–G). Hence,
Asm inhibition did not impair the production of protective
pro-inflammatory cytokines. The high levels of certain pro-
inflammatory cytokines in infected WT/Ami mice could be a
consequence of the increased number of bacteria in their colon
and liver tissues.
Colonic Infiltration of Macrophages Is Not
Impaired by Asm Inhibition
Intestinal macrophages and macrophage-derived IL-12 are
required for the initiation of adaptive immunity in response to
C. rodentium (25). To investigate the role of Asm in mucosal
immunity against C. rodentium infection, we measured the
frequency ofmacrophages in the spleen, mesenteric lymph nodes,
and the colonic lamina propria of WT and WT/Ami mice
infected with C. rodentium. At day 5 and day 10 post infection
the frequencies of macrophages were enhanced in the spleen and
the LP, but no differences were found between infected WT and
infectedWT/Amimice (Figure 4A). Furthermore, the expression
of MHC II, which is essential for the activation of CD4+ T cells,
was not impaired in infectedWT/Amimice compared to infected
WT mice (Figure 4B). These data suggest that the function of
macrophages to initiate adaptive immunity is independent of
Asm during C. rodentium infection.
Asm Inhibition Leads to an Uncontrolled
Expansion of Th1 and Th17 Cells
Infection with C. rodentium is associated with the induction
of Th1 and Th17 adaptive immune responses (26–31). To
measure the CD4+ T cell response during infection of WT
and WT/Ami mice, splenocytes, mLN cells, and LP cells were
restimulated ex vivo and analyzed for IFNγ and IL-17 production
via flow cytometry. Comparable frequencies of Th1 and Th17
cells were detected in uninfected mice treated with or without
amitriptyline. In contrast, C. rodentium infected mice exhibited
enhanced frequencies of IFNγ- and IL-17-producing cells at
day 10 post infection. Compared with infected WT controls,
WT/Ami mice displayed an overall increase in activated T cells,
with highest frequencies of Th1 and Th17 cells at day 10 post
infection (Figures 5A,B).
Regulatory T cells (Tregs) are important to counterbalance
effector T cell responses and to protect from severe pathology
(32). Recently, it was shown that deficiency of Tregs enhances
the susceptibility to C. rodentium infection (32). Therefore, we
assessed the frequencies of Tregs in the spleen, mLN, and LP of C.
rodentium infected WT and WT/Ami mice. No differences were
observed in the spleens and mLN of non-infected and infected
WT mice compared to infected WT/Ami mice. Nonetheless, the
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FIGURE 5 | Enhanced proportions of Th1 and Th17 cells in colonic tissue of amitriptyline treated mice. C57BL/6 mice were treated as described in Figure 2. Single
cells from spleen, mesenteric lymph nodes (mLNs), and lamina propria (LP) were prepared from uninfected WT or WT/Ami mice, 5 and 10 days post C. rodentium
infection, and analyzed for (A) CD4+ IFNγ+ cells (Th1), (B) CD4
+ IL-17+ cells (Th17), or (C) CD4
+FoxP3+ cells (Tregs) by flow cytometry. Percentages of Th1, Th17,
and Tregs from CD4
+ T cells are displayed. All data are presented as mean ± SEM. Statistics were performed using the two-way ANOVA test with Tukey’s multiple
comparison test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
percentage of CD4+Foxp3+ Tregs was significantly decreased in
the LP of infected WT/Ami mice compared to infected WT mice
(Figure 5C). In summary, Asm inhibition enhances the colonic
frequencies of Th1 and Th17 cells in C. rodentium infected
mice, which seems to be a consequence of increased numbers of
bacteria in the colon and a disturbed counterbalanced induction
of Tregs.
Asm Knock-Out Mice Are Strongly
Susceptible to C. rodentium Infection
Amitriptyline was initially introduced in order to treat major
depressive disorders (33). However, nowadays the use of
amitriptyline has expanded to numerous types of pain and other
symptoms (34–38). In addition, anti-inflammatory and anti-
microbial properties of the drug have been reported as well
(39, 40). To exclude eventual drug unspecific effects, we used a
second pharmacological Asm inhibitor, imipramine (Imi) within
the same experimental set up. Well in line with the results from
amitriptyline treated mice, imipramine treated mice are more
susceptible toC. rodentium induced colitis, as shown by increased
bacterial burden in the feces, enhanced colon-weight-to-length
ratios and more severe pathology compared to infected WT
mice (Figures 6A–E).
To prove that the effect in amitriptyline and imipramine
treated animals on C. rodentium induced inflammation is
specifically due to the inhibition of Asm, we repeated the
infection experiments in Asm wild type (Asm WT) and Asm
knock-out (Asm KO) mice. First, we confirmed the specific
depletion of Asm in Asm KO mice under homeostasis and
in infected animals. Therefore, the Asm activity as well as
sphingomyelin and ceramide concentrations were determined
in the colon. As expected, we observed no Asm activity
accompanied with a strong accumulation of sphingomyelin
in non-infected and infected Asm KO mice and only slight
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FIGURE 6 | Imipramine pre-treatment increases the susceptibility to C. rodentium challenge. C57BL/6 mice were either left untreated (WT) or pre-treated with 180
mg/l imipramine in drinking water 2 weeks prior to infection (WT/Imi) and during the course of infection. Mice were orally gavaged with PBS or with ∼2 × 109 colony
forming units (CFUs) of C. rodentium. (A,B) At indicated time points body weight and CFUs in feces in WT mice (white diamonds; n = 4–5) and WT/Imi mice (black
diamonds; n = 4–5) were assessed. Statistics were performed using the Mann–Whitney test. (C) Colon weight-to-length ratio were determined in uninfected,
untreated, and uninfected imipramine treated mice 10 dp C. rodentium infection (n = 4–5). Crypt hyperplasia (D) and inflammation score (E) of uninfected WT and
WT/Imi mice, and WT and WT/Imi mice 10 dp C. rodentium infection (n = 4–5). All data are presented as mean ± SEM. Statistics were performed using the one-way
ANOVA test followed by Tukey’s multiple comparison test (**p < 0.01; ***p < 0.001; ****p < 0.0001).
changes in the ceramide concentrations (Figures 7A–C). To
approve the physiological effect of Asm deficiency in comparison
to amitriptyline mediated inhibition of Asm, we infected
Asm WT and Asm KO mice via oral gavage with ∼2 ×
109 CFUs C. rodentium per mouse and assessed the body
weight, bacterial burden, spleen weight, colon weight-to-
length ratio, and the histopathological score. Importantly, non-
infected Asm WT mice and Asm KO mice exhibited no
difference regarding the analyzed parameters (Figures 7D–F).
In contrast, we observed an enhanced loss of body weight
at day 10 post infection in Asm KO mice compared to
Asm WT mice (Figure 7D). Determination of the bacterial
burden in the feces showed that bacterial loads were higher
in infected Asm KO mice on day 5 and 10 post infection
compared to infected Asm WT mice (Figure 7G). In addition,
a tendency of systemic dissemination in the liver and the
spleen was observed in infected Asm KO mice but not in
infected WT mice (Figures 7H,I). Well in line, also spleen
weights and colon weight-to-length ratios were higher in
infected Asm KO mice than in Asm WT mice (Figures 7E,F).
Finally, the histopathological analysis of colon tissues revealed
significantly elevated crypt hyperplasia and inflammatory
scores in infected Asm KO mice compared to infected Asm
WT mice (Figures 7J–L). In summary, Asm KO mice are
strongly susceptible to C. rodentium infection and show the
same histopathological phenotype as infected amitriptyline
treated animals.
DISCUSSION
The gastrointestinal tract is the largest mucosal surface in the
human body, fulfilling the pivotal role of nutrition and water
absorption. Pathogens preferentially invade the host through the
gastrointestinal tract forcing it to distinguish between harmless
and beneficial bacteria. Thus, the gastrointestinal tract adapted to
these unique circumstances by limiting direct bacterial contact to
the epithelial cell surface, rapid detection and killing of invading
bacteria, and minimizing the exposure of commensal bacteria to
the immune system (41). Dysregulation of this uniquely balanced
system can lead to chronic inflammation, resulting in IBD (42).
Although the exact etiology of IBD remains unclear, the role
of sphingolipids in contributing to the inflammatory process is
evident (4, 5, 43–47). Asm is of particular interest, as it catalyzes
the hydrolysis of sphingomyelin to ceramide, which is the central
molecule in the sphingolipid metabolism. Thus, research on
therapeutic agents able to modulate Asm and tissue-specific
delivery systems or application routes is mandatory (47).
The importance of Asm was first recognized in Niemann-
Pick disease type A and B, also called Acid Sphingomyelinase
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FIGURE 7 | Deficiency of acid sphingomyelinase (Asm) increases susceptibility to C. rodentium infection. Asm wildtype (Asm WT) and Asm knock-out (Asm KO) mice
were orally gavaged with PBS or ∼2 × 109 colony forming units (CFUs) of C. rodentium. Colons were excised from uninfected Asm WT and Asm KO mice and 10 dp
(Continued)
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FIGURE 7 | infection. (A) Asm activity was analyzed in rectal colonic tissue (n = 2–6) by rapid resolution liquid chromatography/mass spectrometry.
(B) Sphingomyelin (n = 4–12) (C) and ceramide (n = 4–12) concentrations are displayed. (D) At indicated time points body weight was assessed in Asm WT mice (n
= 16–17) and Asm KO mice (n = 14–20). Statistics were performed using the Mann–Whitney test or the Student’s t-test. (E) Spleen weight (n = 8–15) and (F) colon
weight-to-length ratio were determined in uninfected, untreated, and uninfected amitriptyline treated mice 5 and 10 dp C. rodentium infection (n = 11–15). (G–I) At
indicated time points CFUs in feces, liver, and spleen of Asm WT mice (n = 11–12) and Asm KO mice (n = 14–15) were assessed. Statistics were performed using the
Mann–Whitney test or the Student’s t-test. (J) Representative H&E staining of colon sections from PBS or C. rodentium infected Asm WT or Asm KO mice 10 dp
infection. [Red lines indicate the crypt length. (L) lumen, (C) crypt. Length of scale bar−50µm]. (K) Crypt length in colons of uninfected Asm WT or Asm KO mice, and
infected Asm WT and Asm KO 10 dp C. rodentium infection (n = 5–9). (L) Histopathology score of the colon of uninfected Asm WT and Asm KO mice, and Asm WT
and Asm KO mice 10 dp C. rodentium infection (n = 5–8). All data are presented as mean ± SEM. Statistics were performed using the two-way ANOVA test followed
by Tukey’s multiple comparison test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Deficiency. Thus, sphingomyelin cannot be metabolized properly
and is accumulated within cells, eventually causing cell death
and the malfunction of major organ systems (10). Of note,
recent studies point out that patients with Niemann-Pick disease
are susceptible to pathogen infections (14, 48), indicating the
association between deficiency and aberrant immune responses.
Well in line, in the present study we identified Asm as a
critical regulator of mucosal immunity to the C. rodentium. Asm
inhibition or Asm deficiency strongly enhanced the susceptibility
to enteric C. rodentium infection.
Interestingly, the impact of Asm and ceramide on IBD is
intensively discussed. Evidence that Asm may be a therapeutic
target in colitis has been demonstrated by a study using the
Asm inhibitor SMA-7. SMA-7 inhibited LPS-induced activation
of NFκB and release of pro-inflammatory cytokines TNFα, IL-
1β, and IL-6 in macrophages (12). This was correlated with
decreased ceramide production. In a chemically induced mouse
model of colitis, oral administration of SMA-7 resulted in
decreased cytokine levels in the colon and lower severity of
colonic injury. Meanwhile, also desipramine and amitriptyline
treatment was shown to inhibit Asm and to decrease pathology
in common acute and chronic epithelial injury colitis models
(13, 49). In all three studies, Asm inhibition resulted in a
decreased pro-inflammatory cytokine production and impaired
lymphocyte infiltration. Importantly, broad immunosuppression
increases the risk of infectious complications (17) and several
enteropathogens have been implicated in the development of
gastrointestinal diseases (50, 51). Infection with Salmonella
(S.) typhimurium results in severe gastroenteritis (52, 53).
The pathogen infects the host by invading macrophages in
Peyer’s patches. Intracellular S. typhimurium survives within the
lysosomal compartment by preventing lysosomal maturation of
the phagosomes (54). Asm activity is required for the release
of the reactive oxygen species that are necessary for the killing
of intracellular S. typhimurium (55). Therefore, Asm deficiency
strongly enhance the susceptible to S. typhimurium infection
(56). Although we also observed a strong susceptibility of Asm
inhibited and Asm deficient mice to C. rodentium infection,
we could not observe any changes in the frequency and
phenotype of macrophages in infected amitriptyline treated mice
compared to infected wild type mice. However, C. rodentium
is a noninvasive, attaching-effacing enteric bacterial pathogen,
which does not infect macrophages but directly interacts with
the intestinal epithelial layer (57). Therefore, it is more likely
that the intestinal barrier is impaired in amitriptyline treated
animals, which is well in line with the enhanced systemic
bacterial distribution of C. rodentium in amitriptyline treated
mice. Indeed, intestinal sphingolipids provide a non-specific
barrier. In a porcine model, inhibition of de novo ceramide
synthesis impaired the proliferation and barrier function of
intestinal epithelial cells, which in turn led to the induction
of inflammation (45). Furthermore, intestinal deletion of serine
palmitoyltransferase (SPT), which is the rate-limiting enzyme for
sphingolipid biosynthesis, significantly decreased the ceramide
and sphingomyelin levels in the plasma membrane of gut cells
and promoted intestinal cell apoptosis with the impairment of gut
barrier function (58). However, further investigation is required
to fully understand the impact of Asm on the barrier function in
infectious and non-infectious colitis.
Th1 and Th17 cells, as part of the adaptive immunity, mediate
the host defense against C. rodentium via the production of
their signature cytokines IFNγ and IL-17 (26, 59), and mice
depleted of either cell type have an impaired ability to clear
the infection (29, 60). However, an uncontrolled CD4+ T cell
response leads to severe immunopathology (20). Interestingly,
we observed a significant increase of Th1 and Th17 cells
accompanied with severe immunopathology in infected mice
with Asm inhibition compared to infected wild type mice. Well
in line, the regulation of murine Th1 differentiation by ceramide
has been reported. A ceramide analog was shown to enhance IL-
12 induced Th1 differentiation with increased T-bet expression
and IFNγ production (61). In contrast, Asm inhibition in human
CD4+ T cells abrogates Th1 cell differentiation (62). In addition,
inhibition of Asm bioactivity by imipramine, which blocks the
generation of ceramide, was shown to impair Th17 generation by
blocking both mTor and Stat3 (63). Interestingly, we showed an
enhanced frequency of Th17 cells in amitriptyline treated infected
mice. Of note, amitriptyline also inhibits in part acid ceramidase,
which metabolizes ceramide to sphingosine. Consequently,
infected Asm inhibited mice displayed increased ceramide
concentrations in the colon compared to infected wild type mice,
which seems to further boost the Th17 response. During C.
rodentium infection, Th1 and Th17 immunity is counterbalanced
by regulatory T cells to inhibit severe immunopathology. Asm
was recently described as negative regulator of Treg development
(64). In comparison to wild type mice, Asm deficient mice
have a higher number of systemic Treg cells under homeostasis.
Furthermore, inhibition of Asm and supplementation of IL-2
result in augmentation of Foxp3 expression as well as induction
of Treg differentiation in vitro (64, 65). Surprisingly, we identified
lower frequencies of Tregs in the colon of infected Asm inhibited
mice compared to infected wild type mice suggesting differences
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in the polarization process under homeostasis and during
infection. Finally, in most of the in vivo studies the Asm inhibitor
was applied intraperitoneally (66–68), whereas we chose the
oral route via the drinking water to specifically target the
gastrointestinal tract. Hence, we cannot exclude that the specific
immunosuppressive micro-milieu in the intestine interferes with
the effects induced by Asm inhibition.
In summary, in contrast to the protective effect of Asm
inhibition in common acute and chronic epithelial injury colitis
models, Asm inhibition or Asm deficiency strongly enhanced
the susceptibility to enteric C. rodentium infection. Therefore,
understanding the sphingolipid enzymes andmetabolic pathways
involved in regulating intestinal inflammation under infectious
and non-infectious conditions is the prerequisite for the
development of new therapeutic strategies, which target the
sphingolipid metabolism.
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